Product Description
Oxybuprocaine is a benzoate ester in which 4-amino-3-butoxybenzoic acidand 2-(diethylamino)ethanol have combined to form the ester bond; an ester-based local anaesthetic (ester "caine") used especially in ophthalmology and otolaryngology. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Oxybuprocaine)
Mechanisms of Action: Sodium Channel Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ocular,Topical,Ophthalmic
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Croatia | Czech | Denmark | Egypt | Estonia | Finland | France | Hungary | Iceland | Ireland | Israel | Jordan | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Sintetica
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Italy
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Anesthesia Related
Phase 2: Keratoconjunctivitis Sicca
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NGF0123 | P2 |
Recruiting |
Keratoconjunctivitis Sicca |
2025-03-31 |
|
| CHL.3-01-2021-M | P3 |
Recruiting |
Anesthesia Related |
2024-12-31 |
|
| CHL.3-01-2021-M | P3 |
Recruiting |
Anesthesia Related |
2024-10-31 |